Immunotherapy for Hodgkin lymphoma: From monoclonal antibodies to chimeric antigen receptor T-cell therapy

Maaroufi, Marouane

doi:10.1016/j.critrevonc.2023.103923

Cited by 2 publications

(3 citation statements)

References 99 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“… 41 , 42 On the other hand, T cell exhaustion, CAR T cell inviability, 43 and the autologous nature of products have limited the safety, efficiency, and availability of new therapeutic methods. 16 , 44 , 45 , 46 Many of these limitations can be overcome using the CRISPR-Cas9-based gene editing tool as an easy and available method. 47 Accordingly, current research efforts are focused on precise CAR T cell engineering with conventional CRISPR-Cas9 systems or novel editors that can generate the desired mutations with or without inducing a double-stranded DNA break into the genome.…”

Section: Crispr Gene Editing Toolmentioning

confidence: 99%

CRISPR, CAR-T, and NK: Current applications and future perspectives

Khoshandam,

Soltaninejad,

Hamidieh

et al. 2024

Genes & Diseases

View full text Add to dashboard Cite

Section: Crispr Gene Editing Toolmentioning

confidence: 99%

CRISPR, CAR-T, and NK: Current applications and future perspectives

Khoshandam,

Soltaninejad,

Hamidieh

et al. 2024

Genes & Diseases

View full text Add to dashboard Cite

“…The majority of patients achieve deep and long-lasting complete remission with standard therapy ( 285 ). However, cases of refractory or relapsing disease still pose an important problem ( 286 ). Furthermore, treatment-related toxicities and side effects, especially in individuals over the age of 60 years, still prove life-threatening and therapy-limiting.…”

Section: Classical Hodgkin-lymphomamentioning

confidence: 99%

“…Classical Hodgkin-Lymphoma (HL) is considered a highly curable disease today. The majority of patients achieve deep and long-lasting complete remission with standard therapy (285). However, cases of refractory or relapsing disease still pose an important problem (286).…”

Section: Current State Of Treatmentmentioning

confidence: 99%

Broadening the horizon: potential applications of CAR-T cells beyond current indications

Karsten,

Matrisch,

Cichutek

et al. 2023

Front. Immunol.

View full text Add to dashboard Cite

Engineering immune cells to treat hematological malignancies has been a major focus of research since the first resounding successes of CAR-T-cell therapies in B-ALL. Several diseases can now be treated in highly therapy-refractory or relapsed conditions. Currently, a number of CD19- or BCMA-specific CAR-T-cell therapies are approved for acute lymphoblastic leukemia (ALL), diffuse large B-cell lymphoma (DLBCL), mantle cell lymphoma (MCL), multiple myeloma (MM), and follicular lymphoma (FL). The implementation of these therapies has significantly improved patient outcome and survival even in cases with previously very poor prognosis. In this comprehensive review, we present the current state of research, recent innovations, and the applications of CAR-T-cell therapy in a selected group of hematologic malignancies. We focus on B- and T-cell malignancies, including the entities of cutaneous and peripheral T-cell lymphoma (T-ALL, PTCL, CTCL), acute myeloid leukemia (AML), chronic myeloid leukemia (CML), chronic lymphocytic leukemia (CLL), classical Hodgkin-Lymphoma (HL), Burkitt-Lymphoma (BL), hairy cell leukemia (HCL), and Waldenström’s macroglobulinemia (WM). While these diseases are highly heterogenous, we highlight several similarly used approaches (combination with established therapeutics, target depletion on healthy cells), targets used in multiple diseases (CD30, CD38, TRBC1/2), and unique features that require individualized approaches. Furthermore, we focus on current limitations of CAR-T-cell therapy in individual diseases and entities such as immunocompromising tumor microenvironment (TME), risk of on-target-off-tumor effects, and differences in the occurrence of adverse events. Finally, we present an outlook into novel innovations in CAR-T-cell engineering like the use of artificial intelligence and the future role of CAR-T cells in therapy regimens in everyday clinical practice.

show abstract

Immunotherapy for Hodgkin lymphoma: From monoclonal antibodies to chimeric antigen receptor T-cell therapy

Cited by 2 publications

References 99 publications

CRISPR, CAR-T, and NK: Current applications and future perspectives

CRISPR, CAR-T, and NK: Current applications and future perspectives

Broadening the horizon: potential applications of CAR-T cells beyond current indications

Contact Info

Product

Resources

About